Meet BIA members redefining TechBio
Driven by world-class science and monumental funding, the UK TechBio sector is undergoing a profound paradigm shift – meet the innovative BIA members leading the charge
Dr Emma Lawrence
Head of Data Tech Policy and Public Affairs, BIA
The landscape of UK life sciences is undergoing a profound paradigm shift. We are firmly in the era of TechBio – a dynamic interface where a tech-first mindset and advanced data engineering converge with biological sciences.
We coined TechBio as the use of cutting-edge AI to transform how we understand complex diseases, discover novel therapeutics and deliver personalised care. The UK is uniquely positioned to lead this global revolution, combining world-class clinical databases, an unparalleled academic ecosystem and a thriving technology sector.
Nowhere is this momentum more evident than within the BIA community. Across our ecosystem, forward-thinking TechBio companies are shifting the boundaries of what is possible. A spectacular case in point is BIA member Isomorphic Labs’ recent announcement of a $2.1 billion Series B raise to scale its AI drug design and push its pipeline toward the clinic. This monumental funding is a massive vote of confidence, not just in one company, but in the UK’s strength at the intersection of AI and life sciences. While financing remains tough for many early-stage companies across the sector, this milestone is a powerful reminder that world-class science with growth ambition can still attract premier global backing. Building on this incredible sector momentum, here are some pioneering AI offerings from some of our remarkable members that are shaping the future of medicine.
Transforming drug discovery: Relation’s "Lab-in-the-Loop" approach
The TechBio revolution is shifting from a quiet transformation to a high-profile reality, a point underscored by new Health Secretary James Murray’s recent visit to the UK-based innovator, Relation Therapeutics. The visit cast a spotlight on how Relation is fundamentally shifting the drug discovery paradigm.
Instead of deploying generic artificial intelligence to parse biased, historical data, Relation is pioneering a true ‘Lab-in-the-Loop’ platform. By creating functional cell atlases derived directly from patient tissue, they map complex disease biology with high resolution. This integration of machine learning with human data ensures that target hypotheses are validated before clinical trials ever begin, dramatically lowering traditional failure rates.
With significant collaborations alongside global giants like Novartis and GSK, and multi-million-dollar backing from NVIDIA’s NVentures, Relation is demonstrating that the future of biotechnology isn't just about faster computation – it's about having absolute confidence in human biology.
AI VIVO: generative simulations for whole-organism biology
A graduate of BIA’s TechBio Boost program, AI VIVO is taking machine learning beyond molecular structures and applying it to complex system dynamics. The company utilises advanced generative AI systems alongside its signature Organome Platform to model biology systematically.
Rather than focusing purely on isolated drug-protein interactions, AI VIVO’s AI engines simulate biological behaviour at the target, organ and whole-organism levels. This top-down simulation allows researchers to model the impact of a therapeutic candidate across full physiological pathways before ever stepping into a wet lab. By dramatically de-risking early-stage research, AI VIVO enables the rapid identification of novel targets and provides unprecedented predictive insight into drug efficacy and safety.
PrecisionLife: unlocking precision medicine beyond oncology
Standard machine learning models often struggle to find clear patterns in noisy, multi-modal healthcare data. PrecisionLife’s unique platform is engineered to generate 10–100x the predictive signal from data compared to traditional AI methods. By analysing the deep biological mechanisms of over 60 complex diseases, PrecisionLife identifies hidden patient subgroups and maps out the distinct mechanisms causing their illness. Their actionable insights and diagnostic tools (Mechanostics®) allow drug developers to stratify clinical trials with high resolution, ensuring the right patient receives the right treatment at the right time.
Mechanome Bio: decoding the forces of disease
Mechanome Bio, however, focuses on mechanobiology – the study of how physical forces and the mechanical properties of cells and tissues influence health and disease.
Mechanome Bio is using proprietary data modelling and computational AI to "decode the mechanics of disease." By integrating spatial cell and tissue mechanomics within multi-modal omics data, the company aims to provide new biomarker and therapeutic opportunities in oncology, fibrosis and chronic diseases. Transforming force into medicine, Mechanome Bio represents the sheer breadth of innovation emerging from the UK TechBio cluster.
The road ahead: nurturing the TechBio ecosystem
The breakthroughs achieved by Isomorphic Labs, Relation Therapeutics, AI VIVO, PrecisionLife and Mechanome Bio highlight a shared truth: Data and AI are the ultimate catalysts for human health. However, for TechBio companies to continue thriving in the UK, the ecosystem requires sustained support. Through our Data, AI and Genomics Advisory Committee (DAGAC), BIA is actively campaigning for robust, ethical and streamlined access to health data, supporting pragmatic AI regulatory frameworks that foster innovation and helping secure sustainable growth capital for scaling SMEs.
Want to stay at the forefront of the technology-biology interface? Join us at TechBio X in Cambridge and find out how your organisation can join our growing community of innovators.
